medRxiv preprint doi: https://doi.org/10.1101/2022.01.23.22269442; this version posted January 25, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

The Epidemiology of Hundreds of Individuals Infected with Omicron BA.1 in Middle-Eastern Jordan

Authors: Rima Hajjo[1,2,3*], Mahmoud M. AbuAlSamen[1], Hamed M. Alzoubi[1,4], Raeda Alqutob[1]

Affiliations:

[1]Jordan CDC, Amman, Jordan (R.H., M.A.S, H.M.Z., R.Q.)

[2]Department of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan (R.H.)

[3]Department of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA (R.H.)

[4]Department of Microbiology and Immunology, Faculty of Medicine, Mutah University, Alkarak, Jordan (H.M.Z)

***Correspondence**

Rima Hajjo. E-mail: rhajjo@gmail.com; r.hajjo@zuj.edu.jo

Keywords: COVID-19, B.1.1.529, BA.1, omicron, SARS-CoV-2, variant of concern (VOC), Jordan CDC.

Abstract

In less than two months of its detection in Jordan, lineage B.1.1.529 recognized as omicron, is constituting 55% of all confirmed COVID-19 infections causing a rise in the daily cases in the

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2022.01.23.22269442; this version posted January 25, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

country. Herein, we report on 500 cases, among the first identified omicron infections in Jordan. We also report on the genomic diversity of 25 omicron viruses identified in nasopharyngeal swabs from Jordan. Our results indicated that 96% of study participants were vaccinated who had asymptomatic, mild or moderate disease. One unvaccinated individual developed severe disease. The median age of omicron cases was 30 years, and most frequent disease symptoms were: fever, coughing, sore throat, runny nose, general fatigue and muscle/joint pain. Viral genomic analysis results revealed that the BA.1 is the dominant omicron sublineage in Jordan, with 45 to 58 total mutations. We identified a few amino acid modifications that could impact the accuracy of some polymerase chain reaction (PCR) tests. In summary, infections caused by BA.1 seem milder than earlier infections. However, it is unknown whether this change is due to alterations in the immunity landscape of the infected population or is the result of viral genetic mutations that reduced viral virulence. Hence, comparing similar studies from different countries is likely to give us a get a better understanding of this variant, its behavior and the impact on disease characteristics.

1. Introduction

A new variant of concern (VOC) for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been recently identified in early November 2021. The variant has been designated as PANGO lineage B.1.1.529(1), and was given the Latin name omicron by the World Health Organization (WHO)(2). B.1.1.529 has further diverged into three sub-lineages: BA.1 (the standard lineage), BA.2 and BA.3. Tracking BA.1 across different geographies is of paramount importance to get a better understanding of this new variant, and assess its impact on disease epidemiology and clinical outcome. Currently, omicron-infections make up 55% of all confirmed COVID-19 cases in Jordan, causing a rise in the daily cases (Figure 1A).

medRxiv preprint doi: https://doi.org/10.1101/2022.01.23.22269442; this version posted January 25, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

In order to get a better understanding of omicron BA.1, we sought to perform epidemiological characterization of the first identified omicron infections to characterize these infections according to gender, age, vaccination status, prior SARS-CoV-2 infections, disease symptoms and symptom severity. We also analyzed all available omicron genomic sequences available from GISAID(3).

2. Materials and Methods

2.1. Epidemiologic Data

Jordan CDC has developed a questionnaire and shared it with collaborators at the Jordanian Ministry of Health to be used by contact tracing teams in order to collect the research data from omicron-infected individuals described here. Data collection by contact tracing teams was conducted using phone-based interviews with confirmed cases. As of January 4th, 2022, 958 records were retrieved and manually curated (*i.e.*, checked for duplications and missing data). A total of 500 cases were finally approved data analysis purposes. Textual data on symptoms were extracted, classified and combined into three levels of severity (mild, moderate and severe) according to Appendix Table 3. All statistics and analysis of proportions were performed in Microsoft® Excel for Mac version 16.57.

A reinfection was defined as being reinfected after 90 days of a prior SARS-CoV-2 infection confirmed with a PCR test. This study was approved by Al-Zaytoonah University Ethics Committee (IRB number: 29/11/2021-2022) and was conducted in accordance with the Declaration of Helsinki.

2.2. Sequencing Data

medRxiv preprint doi: https://doi.org/10.1101/2022.01.23.22269442; this version posted January 25, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Sequencing specimens were collected using original nasopharyngeal swabs. Ion Torrent(4) assembly and Illumina MiSeq(5) were used as genome assembly methods depending on the originating lab. All sequencing specimens were collected by our collaborators at various diagnostic labs mentioned in the acknowledgement. Additional sequencing details are available on GISAID and GitHub: (https://github.com/rhajjo/JCDC_OmicronData).

2.3. Clade and Lineage Assignment

Nextclade in Bioconda version 1.9.0.0(6) has been used to identify mutations in comparison with SARS-CoV-2 reference sequence (WIV04/MN996528.1). Nexclade uses the identified mutations in order to assign the sequences to specific clades and to place them on a reference phylogenetic tree with a subset of all sequences available in GISAID(3).

2.4. Viral Genomic and Amino Acid (AA) Mutations

CoVsurver available from GISAID(3) was used to rapidly screen the omicron genomes to screen AA changes in structural models and highlight if aa changes are close to common drug, host receptor or antibody binding sites.

3. Results and Discussion

3.1. Epidemiological Characterization of the First Complete Set of 500 SARS-CoV-2 Omicron Variant Cases in Jordan

We analyzed contact tracing data from 500 respondents, out of the first 952 confirmed omicron-cases in Jordan, between December 1st thru January 4th, 2022. Raw textual data were manually curated, combined and analyzed to assess omicron-caused infections. Our results, which are based on reported data by infected respondents, revealed that 79.8% of the cases were reported in

medRxiv preprint doi: https://doi.org/10.1101/2022.01.23.22269442; this version posted January 25, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

the capital Amman, while the rest of the cases were distributed among other largely-populated Jordanian cities including Balqa, Irbid and Zarqa. Results showed that 45.8% of all cases were males and 45.0% were females. The median age for the infected individuals was 30 years. Besides, 40.4% of the infections were in age group 25–40 years old (adults), 19.6% in age group 18-23 years old (youth), 7.8% in age group 2-17 years old (children) and 5.8% of all cases were in the age group 60 years old and above.

Symptomatic infections varied in severity and constituted 51.4% of all omicron infections among study respondents, while asymptomatic infections made up 31.4% of the total. Disease symptoms were mostly mild in 88.3% of the symptomatic infections, followed by moderate (9.7%) and severe symptoms (1.9%). The most frequent mild symptoms were fever (47.8%), coughing (47.1%), sore throat, (45.1%), runny nose (33.1%), joint and muscle pain (28.8%), general fatigue (31.5%), headache (13.2%), nasal congestion (16.3%) and hoarseness (9.3%). Notably, loss of taste and smell was only reported in 1.2% of the study cases.

Interestingly, 66.6% of the infected study individuals were fully vaccinated, *i.e.*, had received their complete vaccine doses, and 14 days had already passed since their last dose. Disease symptoms were mainly mild in the fully-vaccinated group. However, individuals who were fully-vaccinated and received a booster shot within the last few months (*i.e.*, 19.1% of the fully-vaccinated group) had asymptomatic infections in 44.1% of the cases, and mild symptoms in 45.5% of the cases, moderate symptoms in 3.9% of the cases, but none had severe disease.

Our results revealed that 8.6% of the study individuals were reinfected with the omicron variant after 90 days from a prior SARS-CoV-2 infection. Most prior infections occurred between October 2020 and March 2021. Interestingly, reinfections ranged in severity from asymptomatic

medRxiv preprint doi: https://doi.org/10.1101/2022.01.23.22269442; this version posted January 25, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

to severe, with the majority being either asymptomatic (41.9%) or mild (44.2%). Nevertheless, 2.3% of the reinfections were moderate, and 2.3% were severe. Epidemiologic results are summarized in Figure 1B. All details on the demographics data are available in Appendix (Appendix Tables 1-5).

3.2. Genomic Characterization of the First 25 Omicron Variant Viruses from Jordan

We analyzed all 25 complete viral genomes from Jordan, corresponding to omicron viruses publicly available on the Global Initiative on Sharing All Influenza Data (GISAID)(7) database prior to January 15th, 2022. Viral genomics data were preprocessed according to the methods described by Rambaut *el al*(8), We retained 23 sequences, which had at least 95% coverage of the reference genome (WIV04/MN996528.1)(9) after trimming the 5′- and 3′-untranslated regions, and excluding sequences with > 5% ambiguous base calls (Ns). A maximum likelihood tree for 23 viruses was estimated, and viral lineages were defined by pangolin(1). DNA sequence variations (SNVs) on the nucleotide and amino acid levels were determined after performing pairwise alignments of the viral sequences with the reference genome WIV04(9) using CoVsurver enabled by GISAID (Appendix).

Omicron genomic sequences from Jordan were all assigned to sublineage BA.1 using Nextclade in Bioconda version 1.9.0.0(11). The analyzed sequences differed in the total number of mutations which ranged from 45 to 58, as shown in Appendix (Appendix Table 6). These mutations included amino acid (AA) deletions and AA substitutions that could impact the sensitivity of many polymerase chain reaction tests (PCR tests) (Figure 1C). In fact, 21 (91.3%) sequences had 5 primer changes and 2 (8.7%) sequences had 3 primer changes in three PCR tests (Table 1). These primer changes impacted the sensitivity of many PCR tests and obligated urgent

medRxiv preprint doi: https://doi.org/10.1101/2022.01.23.22269442; this version posted January 25, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

updates on omicron diagnostic tests. Detailed genomic analysis results are provided on GitHub (https://github.com/rhajjo/JCDC_OmicronData).

5. Conclusions

The observed changes in COVID-19 disease characteristics and omicron's genomic sequences highlight the need for large-scale studies that track the effects of viral mutational changes on disease epidemiology. Moreover, the identified positive impact of vaccines on reducing the severity of symptoms caused by omicron infections could support the ongoing efforts to reduce vaccine hesitancy in Jordan and around the world(12).

Acknowledgments

We gratefully acknowledge the Jordanian Ministry of Health for providing the contact tracing data, in particular we extend our thanks to Dr. Ali Zaitawi, Head of Directorate on Communicable Diseases, and; Dr. Alaa Abu Hudaib, Director of Surveillance. We also acknowledge all the Authors from the Originating and submissting laboratories (Biolab Diagnostic Laboratories, Ministry of Health, Medlabs and Princess Haya Biotechnology Center) responsible for obtaining the specimens, performing the genetic sequencing experiments, reporting and saring the data via the GISAID Initiative (http://www.gisaid.org). RH acknowledges support from the Deanship of Scientific Research at Al-Zaytoonah University of Jordan (Grant number 2020-2019/17/03).

Data Availability

medRxiv preprint doi: https://doi.org/10.1101/2022.01.23.22269442; this version posted January 25, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Data files and results of the genomic analyses are provided on GitHub (https://github.com/rhajjo/JCDC_OmicronData). The authors will make these data publicly available and supply additional details and a readme file upon request.

Supporting Information

Appendix for supplementary information on materials and methods, in addition to Appendix tables 1-6.

Appendix Table 1. Demographic data on omicron-infected cases (n=500).

Appendix Table 2. Disease severity among Omicron-infected cases

Appendix Table 3. Frequency of disease symptoms in symptomatic omicron infections.

Appendix Table 4. Vaccination status among omicron-infected cases.

Appendix Table 5. Reinfection statistics among omicron-infected cases.

Appendix Table 6. List of mutations in 23 omicron viruses from Jordan.

Notes

The authors declare no competing financial interest.

References

1. Cov-Lineages [Internet]. [cited 2022 Jan 17]. Available from: https://cov-lineages.org/global_report_B.1.1.529.html

2. Tracking SARS-CoV-2 variants [Internet]. [cited 2022 Jan 13]. Available from: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants

3. Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data – from vision to reality. Eurosurveillance [Internet]. 2017 Mar 30 [cited 2021 Jan 28];22(13):30494.

medRxiv preprint doi: https://doi.org/10.1101/2022.01.23.22269442; this version posted January 25, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Available from: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2017.22.13.30494

4. Mangul S, Caciula A, al Seesi S, Brinza D, Măndoiu I, Zelikovsky A. Transcriptome assembly and quantification from Ion Torrent RNA-Seq data. BMC Genomics [Internet]. 2014 Jul 14 [cited 2022 Jan 16];15(5):1–11. Available from: https://bmcgenomics.biomedcentral.com/articles/10.1186/1471-2164-15-S5-S7

5. MiSeq System | Focused power for targeted gene and small genome sequencing [Internet]. [cited 2022 Jan 16]. Available from: https://www.illumina.com/systems/sequencing-platforms/miseq.html

6. Package Recipe "nextclade" — Bioconda documentation [Internet]. [cited 2022 Jan 16]. Available from: https://bioconda.github.io/recipes/nextclade/README.html

7. Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data – from vision to reality [Internet]. Vol. 22, Eurosurveillance. European Centre for Disease Prevention and Control (ECDC); 2017 [cited 2021 Feb 1]. p. 1. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388101/

8. Rambaut A, Holmes EC, O'Toole Á, Hill V, McCrone JT, Ruis C, et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nature Microbiology [Internet]. 2020 Nov 1 [cited 2021 Jan 28];5(11):1403–7. Available from: https://doi.org/10.1038/s41564-020-0770-5

9. Zhou P, Yang X lou, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020 579:7798 [Internet]. 2020 Feb 3 [cited 2022 Jan 15];579(7798):270–3. Available from: https://www.nature.com/articles/s41586-020-2012-7

10. PANGO lineages [Internet]. [cited 2021 Jan 28]. Available from: https://cov-lineages.org/pangolin.html

11. Dale R, Grüning B, Sjödin A, Rowe J, Chapman BA, Tomkins-Tinch CH, et al. Bioconda: Sustainable and comprehensive software distribution for the life sciences. Nature Methods. 2018 Jul 1;15(7):475–6.

12. Al-Qerem WA, Jarab AS. COVID-19 Vaccination Acceptance and Its Associated Factors Among a Middle Eastern Population. Frontiers in Public Health. 2021 Feb 10;9:34.

Address for correspondence: Rima Hajjo, 1Department of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, P.O. Box 130 Amman 11733 Jordan.

medRxiv preprint doi: https://doi.org/10.1101/2022.01.23.22269442; this version posted January 25, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

rhajjo@gmail.com; r.hajjo@zuj.edu.jo

Dr. Hajjo is an Assistant Professor of Pharmacogenetics and Pharmacoinformatics at Al-Zaytoonah University of Jordan, an Adjunct Associate Professor at UNC-Chapel Hill, and a Board Member at the National Center for Epidemics and Communicable Disease Control in Amman, Jordan. https://orcid.org/0000-0002-7090-5425

medRxiv preprint doi: https://doi.org/10.1101/2022.01.23.22269442; this version posted January 25, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Table 1. PCR primer changes in omicron viral sequences identified in Jordan.

Nucleotide Change*	Primer†	Number of Sequences‡
C26270T	Charité_E_F	23
C28311T	USCDC_N1_P	23
G28881A	ChinaCDC_N_F	22
G28882A	ChinaCDC_N_F	22
G28883C	ChinaCDC_N_F	22

*Observed nucleotide change in omicron viral genomic sequences identified in Jordan by sequencing. †Impacted primers by the observed nucleotide change. ‡The number of viral genomic sequences from Jordan that contain the nucleotide changes listed in column 1.

Figure 1. Epidemiologic and viral genomic data from omicron cases in Jordan. A) Daily COVID-19 cases and deaths in Jordan over time as of January 16th, 2022. B) Summary statistics of epidemiologic data collected from 500 omicron-infected cases from Jordan. C) Summary statistics of important mutational changes in omicron viruses identified in Jordan and led to PCR primer changes and amino acid changes (deletions and substitutions).

A


Daily Cases
10000
8000
6000
4000
2000
0
Daily Deaths
100
80
60
40
20
0
Cases
Deaths
2/1/2020
5/1/2020
8/1/2020
11/1/2020
2/1/2021
5/1/2021
8/1/2021
11/1/2021
Date

B


% Infections by Sex
46%
45%
9%
Female
Male
Unspecified
% Infections by Age Group
8%
20%
40%
14%
6%
12%
<18
18-24
25-40
24-40
> 60
Unspecified
% Infections by Vaccination Status
8%
8%
84%
Vaccinated
Unvaccinated
Recent Travel History
47%
53%
29%
71%
37%
63%
Traveled in the past 14 days
Did not travel in the past 14 days
Traveled and was in contact with a confirmed infection
Traveled and was not in contact with a confirmed infection
Did not travel and was in contact with a confrmed infection
Did not travel and was not in contact with a confrmed infection
Disease Characteristics
38%
62%
10%
2%
88%
Asymptomatic
Symptomatic
Mild
Moderate
Severe
Most Frequent Symptoms
17%
17%
16%
12%
11%
10%
6%
5%
3%
3%
Fever
Cough
Sore throat
Runny nose
General fatigue
Muscular/joint pain
Nasal congestion
Headache
Voice hoarseness
Shortness of breath

C


Total PCR Primer Changes
2 (8.7%)
21 (91.3%)
2
5
Total AA Deletions
1 (4.3%)
3 (13%)
19 (82.6%)
24
30
39
Total AA Substitutions
1 (4.3%)
2 (8.7%)
1 (4.3%)
2 (8.7%)
1 (4.3%)
1 (4.3%)
1 (4.3%)
1 (4.3%)
4 (17.4%)
1 (4.3%)
3 (13%)
5 (21.7%)
45
46
47
48
49
50
52
53
55
56
57
58